CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic strategies and macromolecular delivery innovations.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and preclinical gene editing technologies without new empirical human data.
PubMed 41812941 · doi:10.1016/j.ijbiomac.2026.151352
What was done
This narrative review summarizes the pathogenic role of apolipoprotein E4 (APOE4) in late-onset Alzheimer's disease, outlines CRISPR-based genome editing strategies (nuclease disruption, base editing, and prime editing) for allele correction, evaluates in vitro and in vivo models, and examines delivery technologies, specifically nanoparticle- and exosome-based platforms.
What was found
The abstract reports established epidemiological risk figures (each APOE4 copy increases Alzheimer's risk approximately 2- to 3-fold, and homozygous carriers have a 10- to 15-fold increased risk versus APOE3 carriers). No new empirical data or quantitative performance metrics are reported. The authors identify crossing the blood-brain barrier as the primary translational bottleneck, along with Cas nuclease immunogenicity, allele specificity, and genomic safety.
Why it matters
Targeting APOE4 at the genomic level offers a potential disease-modifying strategy for the strongest genetic risk factor in Alzheimer's disease, provided macromolecular delivery systems can safely cross the blood-brain barrier.
Limits
As a narrative review, this paper presents no new experimental or human clinical trial data. Delivery efficacy, off-target rates, and long-term safety profiles are discussed conceptually without quantitative comparative data in the abstract.
Cited by
- supports Researchers are actively using gene editing techniques to convert the APOE4 allele into APOE2 in animal models.